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Wolman’s Syndrome. SOS was clinically diagnosed and treatment
began between 7 and 37 days post-HSCT (mean17 days). Pa-
tients were treated per protocol with a starting dose of 10 mg/kg/
day with subsequent increases of 10 mg/kg/day until clinically
therapeutic to a max of 60 mg/kg/day (exception:  2 y/o popu-
lation allowed a maximum of 100 mg/kg/day, n1). The duration
of deﬁbrotide treatment ranged from 13 to 31 days (mean18
days).There were no signiﬁcant complications related to the deﬁ-
brotide infusions or therapy. Seven of 11 (63.6%) patients showed
complete response to the therapy, while 4 patients were classiﬁed
as non-responders. The 100 day post-HSCT survival rate was
54.5% (6/11) for all patients. In conclusion, this study provides
further evidence that deﬁbrotide is an efﬁcacious and safe treat-
ment for pediatric SOS occurring after HSCT.
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Long-term survival for children with neuroblastoma remains
poor despite intensiﬁcation of therapy. Neuroblastoma cells ex-
press a number of potential target antigens for the immune re-
sponse including GD2 and T cells engineered to express chimeric
antigen receptors (CAR) for these antigens might supplement
conventional therapeutics. Unfortunately, modiﬁcation of primary
T cells with CAR has demonstrated limited functionality and
persistence in vivo, likely because the target tumor cells lack the
co-stimulatory molecules required for T cell activation. We have
previously shown that Epstein Barr Virus speciﬁc cytotoxic T
lymphocytes (EBV-CTLs) persist and function in vivo long term,
in part because they receive co-stimulation from EBV infected B
lymphocytes. We reasoned that EBV-CTLs engineered to express
GD2-CAR would also receive such co-stimulatory signals follow-
ing engagement of their native (EBV-speciﬁc) receptors, and hence
would persist longer than primary T cells expressing the same
CAR. We therefore developed a Phase I clinical study to directly
compare EBV CTL-CAR and T-cell CAR. We used two retroviral
vectors distinguishable by a non-expressed marker sequence so that
signal detected in vivo could be assigned to the CTL or the T cells.
Vector use was alternated between the two cell populations. To
date 3 patients received 210E7/m2 of each cell population, while
4 have received 110E8/m2 of each product. We observed no
adverse effects. Even at the low cell doses used to date, signal could
be detected for 6 weeks in peripheral blood. Differential quantita-
tive PCR analysis of the signal showed that EBV-CTL CAR were
present at a higher level and persisted longer than primary T cell
associated CAR. Clinically there has been one mixed response and
two with stable disease, while one patient treated in CR remains
disease free at 12 months. 4 patients have died of progressive
disease. Expressing chimeric antigen receptors in virus speciﬁc T
cells appears to improve lymphocyte survival after adoptive transfer
compared to CAR expression in primary T cells, and may thereby
increase the therapeutic potential of these cells. It will be of interest
to use this approach early after stem cell transplantation, when
residual malignant cells are at their lowest level, and homeostatic
signals will favor expansion of adoptively transferred engineered
CTL.
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We have employed a mouse model for neuroblastoma, AGN2a
cells injected subcutaneously in to strain A/J mice, to demon-
strate that transfection of AGN2a with CD80, CD86, CD54,
and CD137L transforms this lethal cell line in to an effective
cell-based vaccine (AGN2a-4P). When tumor vaccines are ad-
ministered in the context of Treg blockade (with anti-CD25
antibody), the anti-tumor effect is heightened. Our previous
work also demonstrated that the inclusion of CD137L in the
vaccine preparation is uniquely responsible for a strong anti-
tumor T cell response. However, when we switched from tu-
mor-challenge to tumor-bearing regimens the vaccine was in-
effective. Even the inclusion of gene expression vectors
encoding GM-CSF, IL-15, lymphotactin, or SLC did not in-
hibit tumor progression. In order to determine if any impact
could be made in tumor-bearing animals, we initiated a tumor-
bearing model system featuring HSCT. Analysis of lymphoid
reconstitution post-HSCT revealed that up to day 21, mice
remained severely lymphopenic. However, it was during this
time period that vaccination with AGN2a-4P proved most ef-
fective in a tumor-challenge experiment. Moreover, vaccination
early post-HSCT was markedly improved when T cells were
adoptively transferred 3 days after HSCT, just prior to the
initiation of AGN2a-4P vaccination. ELISPOT data with puri-
ﬁed CD4 and CD8 cells indicated that adoptively transferred
lymphocytes early post-conditioning generated an IFN--pro-
ducing tumor-speciﬁc effector population. Furthermore, splenic
reconstitution studies at day 21 clearly indicated that animals
given lymphocyte adoptive transfer had greater percentages of
donor (as opposed to residual host) T cells in their spleens. This
indicates that combining adoptive T cell transfer with HSCT
alters the lymphocyte populations present early post-HSCT,
and that these populations are crucial to the generation of
anti-tumor effector cells. We then tested our post-HSCT vac-
cine strategy in a tumor-bearing model. 1 105 live tumor cells
were given on day -8, TBI on day -1, HSCT consisting of bone
marrow plus 6 106 T cells on day 0, and irradiated AGN2a-4P
vaccine on days 2 and 7. Effective neuroblastoma therapy re-
quired HSCT, T cell transfer and AGN2a-4P vaccination. Our
results support the current practice of autologous HSCT for
neuroblastoma therapy, and suggest that the addition of vacci-
nation and adoptive immunotherapy (T cell transfer) to these
regimens may improve outcomes.
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The role of reduced intensity conditioning (RIC) regimens in
pediatric pts is unclear. To deﬁne the feasibility and toxicity of
this approach using multiple stem cell sources in pediatric pts
ineligible for myeloablative transplant, we conducted a trial at
25 centers participating in the Pediatric Blood and Marrow
Transplant Consortium (PBMTC). Thirty two pediatric pts
(age 2-20yrs, med 12) have been enrolled to date with the
following stem cell sources: 7 related donor (RD) BM (2 mis-
matched); 5 RD-PBSC; 9 unrelated donor (UD) BM; 4UD-
PBSC; 7 UD-CB. Qualifying indications included a previous
allogenic (n15) or autologous (n4) transplant, severe organ
toxicity (n5), invasive fungal infection (n2), and other co-
morbidities, (n 6 pts, 4 with Down syndrome). Diagnoses
included ALL (4 CR2; 9 CR3), AML (6 CR2; 3 CR3; 1 second-
ary), MLL (1 CR3), HD (2 CR3), B-NHL (1 PR3), MDS (2 RA;
Oral Presentations 29
